Track record · closed signal

Boston Scientific Corporation (BSX) — closed signal from October 3, 2025

Partial Published before the outcome was known, scored automatically when the window closed on January 1, 2026 — -2.3% at the close.

Predicted vs. what happened

BSX price · publication thesis → realized outcomesplit-adjusted
$97.59 Published $112.23 Target $95.35 Window close $105.65 Peak
$96.00 – $98.00Entry zone — fair-value band
$97.59Published — price the day we called it
$112.23Target — the price the thesis aimed for
$105.65Peak — highest point inside the window, not a realized return
$95.35Window close — end-of-window price, context only

What happened

Partial

Reached 55% of the predicted growth at its peak, without hitting the target.

At window close
-2.3%
realized, from the publication price to the last close inside the window
Peak gain
+8.3%
peak, from the publication price — not a realized return
S&P 500, same window
+2.2%
SPY over the identical days, dividend-adjusted
Window close
$95.35
last close inside the window, ended January 1, 2026
Peak price
$105.65
peak on November 13, 2025 — not a realized return
Days to target
—

The thesis — published October 3, 2025

Predicted growth
+15%
over the measurement window
Target price
$112.23
the price the thesis aimed for
Entry zone
$96.00 – $98.00
the fair-value band we waited for
Price at publication
$97.59
published October 3, 2025
Confidence
68%
how strongly the data lined up
Timeframe
Short-term (0–3 months)

Boston Scientific looks due for a near-term bounce after a sharp pullback, and trading interest is stronger than usual. A major bank still rates it Buy with a $125 goal, which helps confidence. But the business data is not as strong as the market mood, so patience helps. Prefer buys near $96-$98 with strength showing above $100. Over the next 3 months, a return toward typical levels is possible if buyers stay active, but use tight risk.

Primary drivers

  • Recent drop seems overdone, making a short-term rebound likely
  • Major bank keeps a Buy rating with a $125 goal, boosting confidence
  • Investor mood is upbeat and trading is heavier than usual right now
  • Healthcare device makers have held up well lately, which supports this idea

How it played out

BSX: rebound helped, but the target was not reached

Lyra published BSX at $97.59 on 2025-10-03 with a short-term view for 15% expected growth. The thesis pointed to an overdone recent drop, heavier trading interest, upbeat investor mood, support from healthcare device makers, and a major bank Buy rating with a $125 goal. The preferred entry zone was $96 to $98.

Inside the window, BSX rose to a $105.65 peak on 2025-11-13, a peak gain of 8.3%. That stayed below the $112.23 target. The target was never reached. The stock ended at $95.35 on 2026-01-01. Verdict: the thesis partially played out, but missed its full goal.

What happened during the window

On 2025-10-22, Boston Scientific reported third-quarter adjusted earnings of $0.75 per share on $5.07 billion in revenue, according to Investor's Business Daily. The same report said organic sales rose 15.3%.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Share this receipt

A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All BSX signals